The FTC’s Amgen/Horizon Lawsuit Ends With a Whimper – We covered the FTC’s investigation into (and litigation challenging) Amgen’s $28.3 billion acquisition of rare disease specialist Horizon Therapeutics in our Q1 and Q2 updates….
By: Goodwin
By: Goodwin
